92,105 Shares of Kenvue Inc. $KVUE Acquired by VCI Wealth Management LLC

VCI Wealth Management LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 92,105 shares of the company’s stock, valued at approximately $1,627,000.

Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Kenvue in the 2nd quarter worth approximately $2,882,279,000. Pentwater Capital Management LP purchased a new position in shares of Kenvue during the 2nd quarter valued at approximately $977,094,000. HBK Investments L P increased its holdings in shares of Kenvue by 33.3% during the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after purchasing an additional 7,000,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Kenvue by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock valued at $383,938,000 after purchasing an additional 196,981 shares in the last quarter. Finally, Amundi lifted its stake in shares of Kenvue by 41.2% in the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock valued at $353,216,000 after purchasing an additional 5,392,413 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 0.5%

Shares of KVUE opened at $19.41 on Tuesday. The firm has a market cap of $37.28 billion, a P/E ratio of 16.38, a PEG ratio of 1.77 and a beta of 0.48. Kenvue Inc. has a 12 month low of $14.06 and a 12 month high of $20.13. The stock’s 50 day moving average is $18.41 and its two-hundred day moving average is $18.20. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, hitting the consensus estimate of $0.29. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. Analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is currently 95.45%.

Analyst Ratings Changes

KVUE has been the topic of a number of recent analyst reports. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. UBS Group lifted their price objective on shares of Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a report on Monday. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. HSBC decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Twelve equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $19.44.

About Kenvue

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.